Rob Davis, Merck CEO (Jacquelyn Martin/AP Images)

Mer­ck’s six-year deal strat­e­gy could de­liv­er a block­buster if hy­per­ten­sion drug is OK’d this month

With an FDA de­ci­sion ex­pect­ed next week for its blood pres­sure drug so­tater­cept, Mer­ck is hop­ing that its bun­dle of ac­qui­si­tions in re­cent years will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.